ID: ALA5271797

Max Phase: Preclinical

Molecular Formula: C17H19N5O4S

Molecular Weight: 389.44

Representations

Canonical SMILES:  O=C(CNC(=O)C1CCCC1)Nc1nnc(Cc2ccc([N+](=O)[O-])cc2)s1

Standard InChI:  InChI=1S/C17H19N5O4S/c23-14(10-18-16(24)12-3-1-2-4-12)19-17-21-20-15(27-17)9-11-5-7-13(8-6-11)22(25)26/h5-8,12H,1-4,9-10H2,(H,18,24)(H,19,21,23)

Standard InChI Key:  QZXYNOYOWGNZHF-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 389.44

Molecular Weight (Monoisotopic): 389.1158

AlogP: 2.28

#Rotatable Bonds: 7

Polar Surface Area: 127.12

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 6.83

CX Basic pKa:

CX LogP: 2.13

CX LogD: 1.53

Aromatic Rings: 2

Heavy Atoms: 27

QED Weighted: 0.55

Np Likeness Score: -2.28

References

1. Göricke F, Vu V, Smith L, Scheib U, Böhm R, Akkilic N, Wohlfahrt G, Weiske J, Bömer U, Brzezinka K, Lindner N, Lienau P, Gradl S, Beck H, Brown PJ, Santhakumar V, Vedadi M, Barsyte-Lovejoy D, Arrowsmith CH, Schmees N, Petersen K..  (2023)  Discovery and Characterization of BAY-805, a Potent and Selective Inhibitor of Ubiquitin-Specific Protease USP21.,  66  (5): [PMID:36802665] [10.1021/acs.jmedchem.2c01933]

Source

Source(1):

• Scientific Literature